Sonnet BioTherapeutics Holdings Inc (NAS:SONN) Stock News, Headlines & Updates
Sonnet BioTherapeutics Holdings Inc Stock News from GuruFocus
- 1
Jun 20, 2024
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Marketwired • 8:00am
Jun 13, 2024
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Marketwired • 7:00am
May 28, 2024
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Marketwired • 7:00am
May 22, 2024
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
ACCESSWIRE • 11:00am
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
ACCESSWIRE • 7:00am
May 20, 2024
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
ACCESSWIRE • 11:00am
May 15, 2024
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
ACCESSWIRE • 7:00pm
May 06, 2024
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
ACCESSWIRE • 7:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news